- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06373289
Streef naar zuurstofbereik bij zuigelingen met pulmonale hypertensie (PHOX)
Streefwaarden voor zuurstofverzadiging bij zuigelingen met bronchopulmonale dysplasie-geassocieerde pulmonale hypertensie
Around 50% of infants born extremely preterm develop a chronic lung disease known as bronchopulmonary dysplasia of which some infants will also develop pulmonary hypertension of which 50% of children will die before the age of 2. Physicians are currently limited in their ability to select the most appropriate oxygen targets that will improve outcomes in infants with this condition. This clinical trial will determine whether using different amounts of oxygen improve outcomes in infants with this disease.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Infants born between 22.0 to 31.6 weeks' gestational age with bronchopulmonary dysplasia associated pulmonary hypertension, are receiving supplemental oxygen, and have mature retinas will be randomized to SpO2 targets of either (1) 92-95% (control) or (2) 95-98% (intervention).
Using a cross over design with a 1:1 parallel allocation of infants randomized using a stratified permuted block design. Following 1week of exposure A, infants will cross over to exposure B for 1 week with a 1-week washout period. Bedside providers will follow pre-specified algorithms to maintain oxygen targets during the randomization period. Reports of oxygen saturation performance will also be provided to bedside providers through oxygen saturation histograms.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Samuel Gentle, MD
- Telefoonnummer: 205-541-2247
- E-mail: samjgentle@gmail.com
Studie Contact Back-up
- Naam: Colm Travers
- E-mail: samuel.gentle@yale.edu
Studie Locaties
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35294
- Werving
- The University of Alabama at Birmingham
-
Contact:
- Colm Travers
- Telefoonnummer: 205-934-4011
- E-mail: cptravers@uabmc.edu
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06510
- Werving
- Yale New Haven Hospital
-
Contact:
- Samuel Gentle
- Telefoonnummer: 205-541-2247
- E-mail: samuel.gentle@yale.edu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Between 22w 0/7d and 31w 6/7d gestation at birth
- Diagnosed with echocardiographic pulmonary hypertension (1) >20% flow of blood across the PDA from the pulmonary to arterial circulation, (2) end-systolic flattening of the interventricular septum (eccentricity index >1.3), or (3) right ventricular pressure estimates ≥ 35 mm Hg
- Receiving supplemental oxygen
- Have mature retinas
Exclusion Criteria:
- Major congenital anomalies
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Oxygen saturation target 92-95%
At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 92-95% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed to a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets. |
The intervention will be a cross over exposure to the lower oxygen saturation target. |
|
Actieve vergelijker: Oxygen saturation target 95-98%
At UAB and Yale oxygen saturation targeting is achieved using systematic oxygen saturation histogram monitoring every 3-4 hours by nurse, respiratory therapists, and physicians. Upon randomization to this arm, infants oxygen saturation alarm limits will be adjusted to 95-98% after which an FiO2 modification algorithm will be employed to maintain targets. Daily compliance reports will be generated to ensure oxygen saturation achievement corresponds with oxygen saturation targets. Infants will be exposed for a 1 week period after which they will crossover to the alternative oxygen saturation target with a 1 week washout period in between targets. |
The intervention will be a cross over exposure to the higher oxygen saturation target. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Intermittent hypoxemia event duration
Tijdsspanne: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
The average duration of time (in seconds) an infant's oxygen saturation decrease below 80%. |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Echocardiographic shunting
Tijdsspanne: through study completion, 3 weeks from date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
>20% flow of blood across the PDA from the pulmonary to arterial circulation |
through study completion, 3 weeks from date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Echocardiographic interventricular septal flattening
Tijdsspanne: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
End-systolic flattening of the interventricular septum (eccentricity index >1.3) |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Echocardiographic tricuspid regurgitation
Tijdsspanne: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Right ventricular pressure estimates |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Intermittent hypoxemia frequency
Tijdsspanne: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Number of daily events during which an infant's oxygen saturation decreases below 80% |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Cumulative hypoxemia
Tijdsspanne: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Daily duration during which an infant's oxygen saturation is <80% |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
|
Brain natriuretic peptide
Tijdsspanne: From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
A polypeptide released from the cardiac ventricles indicative of right heart strain |
From date of randomization until 3 weeks have elapsed or date of discharge, whichever came first
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Samuel Gentle, Yale University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 000539476
- 1K23HD113837-01A1 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .